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Abstract: Background: Maximal lung function in early adulthood is an 
important determinant of mortality and COPD.  We investigated whether 
there are distinct trajectories of lung function during childhood, and 
whether these extend to adulthood and infancy. 
 
Methods:  To ascertain trajectories of forced expiratory volume in 1 
second (FEV1), we studied two population-based birth cohorts with repeat 
spirometry from childhood into early adulthood (1046 and 1390 
participants).  To ascertain whether trajectories extend to early life, 
we used a third cohort with repeat lung function measures in infancy 
(V′maxFRC) and childhood (FEV1; n=196).  We identified trajectories using 
latent profile modelling.  We created an allele score to investigate 
genetic associations of trajectories, and constructed a multivariable 
model to identify their early-life predictors.   
 
Results: We identified four childhood FEV1 trajectories: Persistently 
High; Normal; Below Average; and Persistently Low. Persistently Low 
trajectory (~5% of participants) was associated with persistent wheezing 
and asthma throughout follow-up. In genetic analysis, compared with the 
Normal trajectory, the pooled relative risk ratio (95%CI) per allele was: 
0.96 (0.92, 1.01), P=0.10, for Persistently High; 1.01 (0.99, 1.03), 
P=0.49 for Below Average; and 1.05 (1.003, 1.09), P=0.036 for 
Persistently Low. The majority of children in low V′maxFRC trajectory in 
infancy (~75%) did not progress to low FEV1 trajectory in childhood. 
Early-life factors associated with Persistently Low trajectory included 
recurrent wheeze with severe exacerbations, early allergic sensitization, 
and tobacco smoke exposure. 
 
Conclusion: Reducing childhood smoke exposure and minimising the risk of 
early-life sensitization and wheezing exacerbations may reduce the risk 
of diminished lung function in early adulthood.  
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ABSTRACT 
Background: Maximal lung function in early adulthood is an important determinant of mortality and 
COPD.  We investigated whether there are distinct trajectories of lung function during childhood, and 
whether these extend to adulthood and infancy. 
Methods:  To ascertain trajectories of forced expiratory volume in 1 second (FEV1), we studied two 
population-based birth cohorts with repeat spirometry from childhood into early adulthood (1046 and 
1390 participants).  To ascertain whether trajectories extend to early life, we used a third cohort with 
repeat lung function measures in infancy (V′maxFRC) and childhood (FEV1; n=196).  We identified 
trajectories using latent profile modelling.  We created an allele score to investigate genetic associations 
of trajectories, and constructed a multivariable model to identify their early-life predictors.   
Results: We identified four childhood FEV1 trajectories: Persistently High; Normal; Below Average; and 
Persistently Low. Persistently Low trajectory (~5% of participants) was associated with persistent 
wheezing and asthma throughout follow-up. In genetic analysis, compared with the Normal trajectory, 
the pooled relative risk ratio (95%CI) per allele was: 0.96 (0.92, 1.01), P=0.10, for Persistently High; 1.01 
(0.99, 1.03), P=0.49 for Below Average; and 1.05 (1.003, 1.09), P=0.036 for Persistently Low. The 
majority of children in low V′maxFRC trajectory in infancy (~75%) did not progress to low FEV1 trajectory in 
childhood. Early-life factors associated with Persistently Low trajectory included recurrent wheeze with 
severe exacerbations, early allergic sensitization, and tobacco smoke exposure. 
Conclusion: Reducing childhood smoke exposure and minimising the risk of early-life sensitization and 
wheezing exacerbations may reduce the risk of diminished lung function in early adulthood.  
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Research in context 
Evidence before this study 
Early life factors, such as weight at birth, are associated with low lung function and chronic obstructive 
pulmonary disease (COPD) in late adulthood. Lung function development reaches a plateau in early 
adult life, and low lung function in young adults is associated with early mortality from all causes. Failure 
to attain maximal lung function at its plateau is associated with COPD in later life, even when with 
physiological rate of decline of lung function is maintained.  This strengthens the evidence that early life 
influences may be critical for normal lung function growth in childhood and COPD pathogenesis. 
Added value of this study 
Using data from population-based, birth cohort studies, we demonstrated four discrete trajectories of 
FEV1 development from early childhood to young adulthood. Persistently low FEV1 was associated with 
wheezing and asthma through childhood, tobacco smoke exposure and was predicted by severe 
recurrent wheezing and allergic sensitization by age 3 years. We were able to determine from a third 
independent cohort that the majority of infants with low infant lung function trajectory during the first 
year after birth transitioned to normal or above average FEV1 trajectories 
Implications of all the available evidence 
A persistently low trajectory of FEV1 development can be identified during childhood, which is 
associated with potentially modifiable influences in early childhood. This trajectory was replicated in a 
companion study that followed FEV1 growth from childhood to late adulthood. Although perinatal 
factors are associated with low lung function during childhood and with later COPD, the majority of 
infants with low lung function trajectories during the first year appeared to recover to average or above 
average FEV1 growth in later childhood. Interventions to maximise lung growth in early childhood may 
modify the risk of COPD in older age.  
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INTRODUCTION  
Low forced expiratory volume in 1 second (FEV1) in early adult age (at its physiological plateau) is as 
important in the genesis of chronic obstructive pulmonary disease (COPD) as a rapid decline of FEV1 in 
later years.1-3 Furthermore, low lung function in young adult life is associated with early mortality,4 and 
low FEV1 is a marker of premature death from all causes.
5 A recent study by Agusti et al has shown that 
low lung function in early adulthood (around the time of the physiological plateau) is associated with 
earlier onset of COPD, other chronic diseases, and death.6 An accompanying Editorial highlighted the 
need to use longitudinal studies and modern statistical approaches to gain better understanding of the 
causal pathways, understand the critical windows for lung function development, and identify targets 
for early intervention.4,5,7-11   
Hypothesis-driven analyses in unselected longitudinal cohorts and children with asthma have shown 
that lung function in adult life is in part determined by childhood events. The observation that FEV1 was 
consistently lower amongst individuals with clinical phenotypes such as severe asthma,8 and persistent 
wheezing9 provided foundations for the concept that lung function tracks from school-age to 
adulthood.9,10 This is supported by the data-driven analysis of spirometry records from childhood (age 11 
years) to the fourth decade of life in Tucson cohort, which identified two distinct lung function 
trajectories (low and normal).11 Persistently low trajectory comprised nearly 10% participants, and 
individuals in this class were predisposed to COPD later in life.  
We hypothesized that a population comprises several distinct groups of individuals with similar lung 
function trajectories from pre-school age to adolescence, which extend to the physiological plateau in 
early adulthood, and that these trajectories are in part established at birth. However, factors which 
determine lung function growth may differ from those affecting the rate of decline after the plateau,12 
and inference from models that combine a limited number of measures in childhood (before peak lung 
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function is reached in early adulthood), with those in later adulthood (during the decline phase), may 
not adequately disaggregate the effects of risk factors which differentially impact growth and decline.  
To address our hypotheses, and ascertain trajectories during the lung function growth and their risk 
factors, we combined data from three population-based birth cohorts in which lung function was 
assessed on multiple occasions from infancy, through early school age and adolescence, into early 
adulthood. We first set out to establish whether a method to categorise FEV1 trajectories using latent 
profile analysis could be applied across different cohorts, and whether it yields consistent results across 
different populations. We proceeded to identify genetic and early-life factors associated with FEV1 
trajectories at the population level. Finally, we investigated whether FEV1 trajectories track back to lung 
function patterns in infancy.    
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METHODS 
Study design, setting and participants 
We studied three population-based birth cohorts: Manchester Asthma and Allergy Study (MAAS)13 and 
the Avon Longitudinal Study of Parents and Children (ALSPAC)14 from the UK STELAR consortium15, and 
the Australian Perth Infant Asthma Follow-up (PIAF) study.16 All participants were recruited prenatally 
and followed prospectively. All studies were approved by research ethics committees. Informed consent 
was obtained from parents, and study subjects gave their consent when applicable. 
Data sources/measurement  
We investigated trajectories of FEV1 from early school-age to adolescence in MAAS
13 and replicated 
these using data from ALSPAC from school age to early adultood14. We ascertained whether FEV1 
trajectories extended to lung function in early infancy using data from PIAF.17   
We performed spirometry according to ATS/ERS criteria18,19 at ages 5, 8, 11 and 16 years in MAAS; ages 
8, 15 and 24 years in ALSPAC; and 6, 12 and 18 years in PIAF. We expressed FEV1 as % predicted at each 
age.20 In  PIAF, we assessed infant lung function at ages 1, 6 and 12 months using the rapid 
thoracoabdominal compression test to determine the maximal flow at functional residual capacity 
(V′maxFRC).
16,17 In MAAS we measured specific airways resistance (sRaw) at age 3 years.
21 In MAAS and 
ALSPAC, we measured post-bronchodilator FEV1 after administration of 400 g of salbutamol (5, 11 and 
16 years in MAAS, and 15 and 24 years in ALSPAC), and assessed assessed airway hyper-reactivity (AHR) 
using methacholine challenge.22  
Details of clinical follow up, genotyping (MAAS and ALSPAC), and definitions of clinical outcomes 
(asthma,23 wheeze phenotypes,24 severe asthma exacerbations,25 airway hyper-reactivity (AHR),26 lower 
respiratory tract infections [LRTIs]27), and environmental exposures are presented in the supplementary 
appendix. 
7 
 
Statistical Analysis 
Longitudinal profile analysis to assess prototypical FEV1 trajectories: We used a latent profile model to 
assign children to their most likely group based on the profile of FEV1 over time. Latent profile modelling 
has been described extensively elsewhere.28 Briefly, we assumed that each child belonged to one of a 
set of N latent profiles, the number or size of which were unknown a priori. We used two-level random 
intercept and random coefficients regression models to examine trajectory classes with no change over 
time, and under the assumption that the profile of FEV1 changes linearly over time. The models were 
compared for goodness-of-fit using the Bayesian Information Criterion (BIC). For each child, the 
posterior probability of belonging to each of the classes was calculated, and children were assigned to 
the latent profile with the largest probability. Latent profile modelling was carried out using the gllamm 
(generalised linear latent and mixed models) package implemented in Stata (StataCorp, College Station, 
TX).  Characteristics of trajectories were investigated using multinomial regression.  
Genetic associations with FEV1 trajectories:  We constructed a weighted allele score from 77 SNPs found 
to have genome-wide evidence for association with FEV1/FVC, or FEV1 decline in adults
29 (Table S1, 
supplementary appendix). The dosage of the risk allele at each locus was multiplied by a SNP-specific 
weight (linear coefficient [beta] divided by the average of 77 linear coefficients), then averaged across 
SNPs.  SNP-specific risk alleles and weights were based on the reported meta-analysis.29 The units of the 
derived genetic score were per-beta per-SNP. Setting the ‘Normal’ trajectory as the baseline group, we 
used a multinomial logistic regression model to investigate the risk of the membership of other 
trajectories per 1-unit increase of the genetic score. The independent associations of the resulting 
genetic risk score with FEV1 trajectories in MAAS and ALSPAC were meta-analysed with fixed and 
random effect models using the method of Mantel and Haenszel (metan command in Stata). Using 
multinomial logistic regression models, we also calculated the relative risk ratios for ‘Persistently Low’ 
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(vs. ‘Normal’ trajectory) in extreme quantiles of the allelic risk score in two cohorts independently 
(deciles in ALSPAC; eight quantiles in MAAS). 
Identification of the early-life predictors of FEV1 trajectories:  We constructed a multivariable regression 
model to identify early-life predictors of subsequent latent profiles of FEV1. We carried out these 
analyses in MAAS, in which we had richer data collected in early life.  We used receiver operating 
characteristic (ROC) curves to evaluate the predictive ability of these predictors. 
Role of the funding source 
The study sponsors had no role in study design; in the collection, analysis, and interpretation of data; in 
the writing of the report; or in the decision to submit the paper for publication.  
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RESULTS 
We included 1046 participants from MAAS, 1390 from ALSPAC, and 196 from PIAF. Participant flow is 
presented in the Supplementary appendix.  
FEV1 trajectories from early school-age to young adulthood (MAAS and ALSPAC) 
We selected 4-class model in MAAS and ALSPAC (please see Supplementary appendix and Table S2).  
The posterior probability of class membership was high in both cohorts (Table S3). The proportion of 
participants and the mean FEV1 over time in each of the classes were similar across the cohorts (Table 
S4).  We labelled the classes (FEV1 trajectories) as: (1) Persistently High; (2) Normal; (3) Below Average; 
and (4) Persistently Low (Figure 1). Children within these four trajectories had stable lung function that 
tracked from age 5 to age 16 years (MAAS), and from ages 8 to 24 years (ALSPAC), with no overlap in 
FEV1 at any time. The solutions remained stable and results unchanged when we included only children 
who had spirometry on at least 3 follow-ups (Tables S5-6).   
Characteristics of children in each of the FEV1 trajectories are shown in Tables S7 and S8. Persistently 
Low trajectory was consistently associated with wheeze and asthma throughout the follow-up in both 
cohorts; in MAAS, almost half the children in this trajectory had asthma, and in ALSPAC this was 
approximately one third, significantly higher than in the rest of the population. The proportion of 
children with LRTIs in the first 3 years (data from medical records, available only in MAAS27) was 
significantly higher in the Persistently Low trajectory (32.3%) compared to the Normal trajectory 
(12.1%). Post-bronchodilator FEV1 and FEV1/FVC followed similar patterns as the baseline FEV1 in both 
cohorts. In MAAS, sRaw at age 3 years was significantly higher in Persistently Low compared to other 
trajectories, indicating diminished lung function (P=0.001). Persistently Low trajectory was significantly 
associated with AHR in both cohorts. There was no association between trajectory membership and 
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allergic sensitisation in adolescence in MAAS, or at age 7 years in ALSPAC. Sensitisation in early 
childhood in MAAS was significantly more common in Persistently Low trajectory.  
There was no difference in gender between trajectories. Birth weight was significantly higher in the 
Persistently High trajectory in ALSPAC, but not in MAAS. In MAAS, children in the Persistently High 
trajectory were less likely to be exposed to environmental tobacco smoke (ETS) compared to all others 
(Figure 2a). Children continuously exposed to ETS from birth to age 16 years were at increased risk of 
belonging to the Below Average and Persistently Low trajectories. We observed similar trends in 
ALSPAC, with Persistently High trajectory having the lowest proportion of ETS-exposed participants 
(Figure 2b). 
Genetic associations  
Genotyping data was available in 927 participants in ALSPAC, and 902 in MAAS. The weighted genetic 
score based on 77 SNPs was inversely associated with the order of FEV1 trajectories (Persistently High to 
Persistently Low) in both cohorts (Table S9). The meta-analysis is shown in Figure 3: compared with the 
Normal trajectory, the pooled relative risk ratio (95%CI) per allele was: 0.97 (0.92, 1.01), P=0.13, for 
Persistently High; 1.01 (1.00, 1.03), P=0.49 for Below Average; and 1.05 (1.00, 1.09), P=0.036 for 
Persistently Low. Results using the inverse variance method were very similar. Risk of Persistently Low 
FEV1 (vs. Normal) in 10
th decile of risk score (vs. 1st decile) was 2.03 (0.62, 6.67), p=0.24 in ALSPAC. In 
MAAS, the risk of Persistently Low FEV1 in the highest compared with the lowest of eight quantiles was 
4.19 (0.83-21.05), p=0.08. 
Do FEV1 trajectories extend back to lung function in early life (PIAF)? 
In PIAF, a 3-class model provided the optimal solution for FEV1 (Above Average, Normal and Below 
Average, Figure 4a), and a 2-class model for V′maxFRC (Above Average and Below Average, Figure 4b). 
Among children in the Below Average FEV1 trajectory, V′maxFRC was significantly lower compared to other 
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trajectories at age 1 month (P=0.05) and 6 months (P=0.018), but not at age 1 year (Table S10). Although 
children in the Below Average V′maxFRC trajectory were significantly more likely to remain in the Below 
Average FEV1 trajectory (OR=3.63, 95%CI 1.21–10.90, P=0.022), the majority of these children (~75%) 
transitioned to the Above Average (12.2%) or Normal (63.4%) FEV1 trajectories in later childhood (Figure 
4, panel c). 
Early-life predictors of FEV1 trajectories (MAAS) 
Children with recurrent severe wheeze exacerbations by age 3 years, with allergic sensitization at age 3 
years, and who have been exposed to ETS by age 3 years, were more likely to belong to the Persistently 
Low trajectory (Table S10). This set of variables provided a good predictive ability in MAAS for 
discriminating between subjects in Persistently Low from Persistently High trajectory (Figure 5, Area 
Under the ROC Curve-AUROC=90.7%, sensitivity=81.8%; specificity=80.95%), and a fair predictive ability 
for discriminating between subjects in Persistently Low from all others (Figure S1, AUROC=77.2%, 
sensitivity=81.8%; specificity=67.8%). 
We found an association between low birth weight and low childhood FEV1 trajectories. In MAAS, which 
included no preterm infants, low birth weight (LBW) at term (<2500g) was associated with Peristently 
Low FEV1 (Odds ratio 3.39 [95% CI 0.98-11.77], p=0.055). In ALSPAC, LBW adjusted for preterm (<37 
weeks) gestation at birth was associated with Persistently Low FEV1 (OR 1.98 [0.65-5.99], p=0.226, and 
Below Average FEV1 (OR 1.84 [0.91-3.73], p=0.09).   
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DISCUSSION 
In two population-based birth cohorts, using data-driven analyses we identified four distinct lung 
function trajectories extending from early school age, through mid-school age, into adolescence and 
early adulthood. Subjects assigned to the Persistently Low trajectory, representing approximately 1 in 20 
participants, had low lung function in the third decade of life, around the time of the physiological 
plateau. Individuals in this trajectory had FEV1 below 80% predicted from early childhood to the point 
beyond which lung function starts to decline with aging.3,20 In the Persistently Low trajectory, both 
baseline and post-bronchodilator FEV1 was up to 25% lower, and FEV1/FVC up to 10% lower than the 
next lowest category. This tracking of lung function from early school-age is consistent with previous 
reports from population-based studies9,10, and provides confirmatory empirical evidence of this 
phenomenon based on a hypothesis-free approach. In addition to using data-driven analyses, another 
novel feature of the present study was the extension of lung function trajectories to early childhood, 
where spirometry is not practicable, and the observation that “low” lung function recovered in the 
majority of cases. At group level, children in the Low FEV1 trajectory in PIAF had significantly diminished 
lung function in infancy (measured by V′maxFRC), which is very similar to the finding in MAAS that, as a 
group, those in Persistently Low FEV1 trajectory had significantly diminished lung function at age 3 years 
(measured by sRaw). However, comparison of lung function trajectories in infancy and in school-age in 
PIAF has shown that although infants in the Below Average V′maxFRC trajectory were significantly more 
likely than children in the higher V’maxFRC categories to be classified in the Below Average FEV1 trajectory 
in childhood, the majority of these children (~75%) transitioned to the Above Average (12.2%) or Normal 
(63.4%) FEV1 trajectories. These findings are consistent with previous results from PIAF obtained using 
standard hypothesis-testing analyses,17,30 and support the concept of postnatal “recovery” of low 
neonatal lung function. The application of the same data-driven approach to longitudinal analysis as 
used in the MAAS, ALSPAC and Tasmanian Longitudinal Health Study (TAHS),31 allows some inference to 
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the general population on the patterns of lung function from one month of age to the sixth decade. 
Disaggregation of this population into discrete trajectories suggests that the opportunity for lung 
function recovery extends beyond the neonatal period. 
Our data revealed no evidence of groups of children with declining FEV1. A report from TAHS published 
in this issue of the journal, which used a similar statistical approach to discovery of lung function 
trajectories and spanned childhood (7-18 years) and later adulthood (45-55 years), described six 
trajectories, four of which were strikingly similar to ours.31 One further trajectory with below average 
FEV1 by age 18, and accelerated decline in later adulthood after reaching the plateau, could not be 
captured within our data set. This trajectory was characterized by both childhood factors and personal 
smoking in adulthood, which were independent risk factors. Together, our studies and TAHS elucidate 
the developmental patterns of lung function through the life-course, confirm their link with COPD, and 
provide evidence that different factors affect lung function growth from those affecting lung function 
decline. We have shown that Persistently Low trajectory is determined by both genetic factors and 
early-life events. We showed relatively weak evidence that SNPs discovered through GWAS of adult lung 
function29 were associated with a low childhood trajectory of FEV1. This suggests an influence of at least 
some of the included variants on lung function in early life but, as they were derived from studies of 
adults, it is likely that they consisted of a combination of factors influencing lung function growth and 
decline. A recent study of adults with repeat lung function measures showed that genetic variants 
associated with cross-sectional lung function in adults were not associated with longitudinal decline, 
suggesting that some of the observed association may be explained by developmental influences32. We 
did not have sufficient statistical power in this sample to investigate the individual contributions of risk 
alleles, nor to construct a de novo GWAS. 
Individuals with Persistently Low FEV1 in childhood have low maximally attained lung function in early 
adulthood, and are consequently at higher risk of COPD31, with or without additional adverse exposures 
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in adulthood. Personal smoking acts as an independent risk factor which contributes to accelerated lung 
function decline in middle adulthood, predominantly among individuals with below average lung 
function.31 In this group, in addition to early-life risk factors contributing to the diminished lung function 
at physiological plateau, adverse exposures in adult life lead to COPD development. Childhood asthma 
and early-life LRTIs are associated with low lung function trajectories and higher COPD risk in both 
scenarios. We found an association between asthma reported at all available ages and persistently Low 
FEV1 trajectory. This is consistent with previously reported associations between persistent asthma in 
childhood and subsequent lung function,8, 9 but we acknowledge the potential for misclassification of 
symptoms associated with pre-existing airway obstruction and asthma diagnosis, particularly when 
relying on self-report from questionnaires for the latter. This limits interpretation of the causal pathway 
between asthma in childhood and low lung function trajectories in later life. 
Although children with severe wheeze and early sensitization had lower FEV1 throughout childhood, 
their FEV1 remained relatively stable. In contrast, a recent study of FEV1 trajectories between ages 7 and 
26 years among patients with childhood asthma described two trajectories characterized by decline 
(Normal growth and early decline, and Reduced growth with early decline).33 However, direct 
comparison with our findings is not possible, as our cohorts are population-based, and we used data-
driven approach rather than predetermined categorization to identify trajectories. In MAAS, similar 
proportions of children (approximately one third) in Persistently Low trajectory had persistent wheeze 
and transient early wheeze, whist <10% had late-onset wheezing.  This is in contrast with the Australian 
high-risk cohort, which suggested that only persistent wheeze is associated with reduced growth in FEV1 
over adolescence, but that transient wheeze is a benign condition with no sequelae.34 In MAAS, an 
important predictor of subsequent Persistently Low FEV1 trajectory was severe exacerbation of 
wheezing in early life, rather than only wheezing persistence.  Low birth weight, which is associated with 
tobacco some exposure during pregnancy and early onset wheezing in infancy was associated with low 
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childhood FEV1 trajectories in our study independently of preterm delivery. This may be explained by 
restricted intrauterine growth influencing airway development and subsequent lung function35 with an 
associated tendency to wheezing in the context of LRTIs. 
Persistently Low lung function trajectory was also identified in the Tucson cohort (comprising nearly 10% 
participants),11 and is remarkably similar to our Persistently Low trajectory, which comprised a sizeable 
proportion (3.4%-6.7%) of our study populations. Assuming that 13.3% of the population develop COPD 
(http://www.hse.gov.uk/Statistics/causdis/copd/copd.pdf), and that among these, subjects in the 
Persistently Low trajectory would likely be diagnosed with COPD,34 the calculated population 
attributable risk is 22.9%-46.7%. This also represents the estimated reduction in COPD which would 
occur if early interventions improve lung function for this group. To inform potential strategies for 
improving lung function in early adulthood, we have identified early-life risk factors associated with 
Persistently Low trajectory, which included early-life ETS exposure, recurrent severe exacerbations of 
wheezing, and early allergic sensitisation. A recent study suggested that adult smoking, but not parental 
smoking history, can negatively influence adult lung function trajectory and modify the adverse impact 
of early-life exposures.35 Our and TAHS data demonstrate that both are important. We identified an 
association between the absence of early-life tobacco smoke exposure and Persistently High trajectory, 
which In TAHS had markedly lower risk of COPD at age 55 years.31 Thus, while tobacco smoke exposure 
will not necessarily lead to a disease, the absence of this exposure is associated with exceptionally good 
lung function and subsequent health. The risk of being in one of the diminished lung function profiles 
was decreased by 76% among children who were not exposed to parental smoking, suggesting that ETS 
exposure in early childhood may be causally related to COPD development, and that this may be 
mediated via the effect of early-life exposure on subsequent trajectories of lung function into 
adulthood.  
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Strengths and limitations 
One of the limitations of our study is that it was not possible to have identical measures of lung function 
through the life-course in our cohorts. We did not measure spirometry before age five years, since 
forced expiratory manoeuvres are difficult to carry out in young children. We used different cohorts and 
age-appropriate measures of pulmonary function to make inference about the life-course (rapid 
thoraco-abdominal compression in infancy16, plethysmography in pre-school age36, spirometry from 
school age onwards), which may represent the best available approximation of what might be 
happening from birth to adulthood. Another limitation is that the questions we used contained small 
differences in wording.37 ALSPAC included pre-term babies, which may explain slightly higher proportion 
of children in the Persistently Low trajectory in ALSPAC (6.7%, compared to 3.4% in MAAS).  One of the 
strengths of this study is the ability to disambiguate the temporal structure of profiles during childhood, 
allowing us to identify patterns during the lung function growth phase. It is striking that although we 
modelled data collected at different time points, and separately for each cohort, the results indicated 
almost identical latent profiles. In PIAF, we did not observe Persistently Low FEV1 trajectory.  This is not 
surprising, given a relatively small proportion of children in this trajectory (~5%), and a considerably 
smaller size of PIAF compared to MAAS and ALSPAC. 
We wish to emphasise that our current study is exploratory in nature. Therefore, the results should 
be interpreted with caution, and need to be validated in a larger population. We are also cognizant of 
the potential effect of the withdrawal/missing data rates. We carried out our analyses under the 
assumption that data was missing at random. To test this assumption, we carried out analyses using 
both children with at least three data points available, and those with at least one time point. Both 
analyses gave consistent optimal goodness-of-fit using the BIC, and the child class assignments were 
stable across the two analyses. This suggests that the missing at random assumption was plausible, 
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given that if children with missing data points were not missing at random, there would have been a 
higher mismatch between classes. 
Conclusion 
Using data from population-based birth cohort studies, we demonstrated four discrete trajectories of 
FEV1 development from early childhood to young adulthood. Interventions to reduce the risk of 
Persistently Low FEV1 trajectory should start in early childhood, and should include aggressive strategies 
to reduce tobacco smoke exposure, and novel strategies to prevent early-life sensitization and 
exacerbations of early-childhood wheezing.   
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ABSTRACT 
Background: Maximal lung function in early adulthood is an important determinant of mortality and 
COPD.  We investigated whether there are distinct trajectories of lung function during childhood, and 
whether these extend to adulthood and infancy. 
Methods:  To ascertain trajectories of forced expiratory volume in 1 second (FEV1), we studied two 
population-based birth cohorts with repeat spirometry from childhood into early adulthood (1046 and 
1390 participants).  To ascertain whether trajectories extend to early life, we used a third cohort with 
repeat lung function measures in infancy (V′maxFRC) and childhood (FEV1; n=196).  We identified 
trajectories using latent profile modelling.  We created an allele score to investigate genetic associations 
of trajectories, and constructed a multivariable model to identify their early-life predictors.   
Results: We identified four childhood FEV1 trajectories: Persistently High; Normal; Below Average; and 
Persistently Low. Persistently Low trajectory (~5% of participants) was associated with persistent 
wheezing and asthma throughout follow-up. In genetic analysis, compared with the Normal trajectory, 
the pooled relative risk ratio (95%CI) per allele was: 0.96 (0.92, 1.01), P=0.10, for Persistently High; 1.01 
(0.99, 1.03), P=0.49 for Below Average; and 1.05 (1.003, 1.09), P=0.036 for Persistently Low. The 
majority of children in low V′maxFRC trajectory in infancy (~75%) did not progress to low FEV1 trajectory in 
childhood. Early-life factors associated with Persistently Low trajectory included recurrent wheeze with 
severe exacerbations, early allergic sensitization, and tobacco smoke exposure. 
Conclusion: Reducing childhood smoke exposure and minimising the risk of early-life sensitization and 
wheezing exacerbations may reduce the risk of diminished lung function in early adulthood.  
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Research in context 
Evidence before this study 
Early life factors, such as weight at birth, are associated with low lung function and chronic obstructive 
pulmonary disease (COPD) in late adulthood. Lung function development reaches a plateau in early 
adult life, and low lung function in young adults is associated with early mortality from all causes. Failure 
to attain maximal lung function at its plateau is associated with COPD in later life, even when with 
physiological rate of decline of lung function is maintained.  This strengthens the evidence that early life 
influences may be critical for normal lung function growth in childhood and COPD pathogenesis. 
Added value of this study 
Using data from population-based, birth cohort studies, we demonstrated four discrete trajectories of 
FEV1 development from early childhood to young adulthood. Persistently low FEV1 was associated with 
wheezing and asthma through childhood, tobacco smoke exposure and was predicted by severe 
recurrent wheezing and allergic sensitization by age 3 years. We were able to determine from a third 
independent cohort that the majority of infants with low infant lung function trajectory during the first 
year after birth transitioned to normal or above average FEV1 trajectories 
Implications of all the available evidence 
A persistently low trajectory of FEV1 development can be identified during childhood, which is 
associated with potentially modifiable influences in early childhood. This trajectory was replicated in a 
companion study that followed FEV1 growth from childhood to late adulthood. Although perinatal 
factors are associated with low lung function during childhood and with later COPD, the majority of 
infants with low lung function trajectories during the first year appeared to recover to average or above 
average FEV1 growth in later childhood. Interventions to maximise lung growth in early childhood may 
modify the risk of COPD in older age.  
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INTRODUCTION  
Low forced expiratory volume in 1 second (FEV1) in early adult age (at its physiological plateau) is as 
important in the genesis of chronic obstructive pulmonary disease (COPD) as a rapid decline of FEV1 in 
later years.1-3 Furthermore, low lung function in young adult life is associated with early mortality,4 and 
low FEV1 is a marker of premature death from all causes.
5 A recent study by Agusti et al has shown that 
low lung function in early adulthood (around the time of the physiological plateau) is associated with 
earlier onset of COPD, other chronic diseases, and death.6 An accompanying Editorial highlighted the 
need to use longitudinal studies and modern statistical approaches to gain better understanding of the 
causal pathways, understand the critical windows for lung function development, and identify targets 
for early intervention.4,5,7-11   
Hypothesis-driven analyses in unselected longitudinal cohorts and children with asthma have shown 
that lung function in adult life is in part determined by childhood events. The observation that FEV1 was 
consistently lower amongst individuals with certain clinical phenotypes (such as severe asthma,8 and 
persistent wheezing9) provided foundations for the concept that lung function tracks from school-age to 
adulthood.9,10 This is supported by the data-driven analysis of spirometry records from childhood (age 11 
years) to the fourth decade of life in Tucson cohort, which identified two distinct lung function 
trajectories (low and normal).11 Persistently low trajectory comprised nearly 10% participants, and 
individuals in this class were predisposed to COPD later in life.  
We hypothesized that a population comprises several distinct groups of individuals with similar lung 
function trajectories from pre-school age to adolescence, which extend to the physiological plateau in 
early adulthood, and that these trajectories are in part established at birth. However, factors which 
determine lung function growth may differ from those affecting the rate of decline after the plateau,12 
and inference from models that combine a limited number of measures in childhood (before peak lung 
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function is reached in early adulthood), with those in later adulthood (during the decline phase), may 
not adequately disaggregate the effects of risk factors which differentially impact growth and decline.  
To address our hypotheses, and ascertain trajectories during the lung function growth and their risk 
factors, we combined data from three population-based birth cohorts in which lung function was 
assessed on multiple occasions from infancy, through early school age and adolescence, into early 
adulthood. We first set out to establish whether a method to categorise FEV1 trajectories using latent 
profile analysis could be applied across different cohorts, and whether it yields consistent results across 
different populations. We proceeded to identify genetic and early-life factors associated with FEV1 
trajectories at the population level. Finally, we investigated whether FEV1 trajectories track back to lung 
function patterns in infancy.    
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METHODS 
Study design, setting and participants 
We studied three population-based birth cohorts: Manchester Asthma and Allergy Study (MAAS)13 and 
the Avon Longitudinal Study of Parents and Children (ALSPAC)14 from the UK STELAR consortium15, and 
the Australian Perth Infant Asthma Follow-up (PIAF) study.16 All participants were recruited prenatally 
and followed prospectively. All studies were approved by research ethics committees. Informed consent 
was obtained from parents, and study subjects gave their consent when applicable. 
Data sources/measurement  
We investigated trajectories of FEV1 from early school-age to adolescence in MAAS
13 and replicated 
these using data from ALSPAC from school age to early adultood14. We ascertained whether FEV1 
trajectories extended to lung function in early infancy using data from PIAF.17   
We performed spirometry according to ATS/ERS criteria18,19 at ages 5, 8, 11 and 16 years in MAAS; ages 
8, 15 and 24 years in ALSPAC; and 6, 12 and 18 years in PIAF. We expressed FEV1 as % predicted at each 
age.20 In  PIAF, we assessed infant lung function at ages 1, 6 and 12 months using the rapid 
thoracoabdominal compression test to determine the maximal flow at functional residual capacity 
(V′maxFRC).
16,17 In MAAS we measured specific airways resistance (sRaw) at age 3 years.
21 In MAAS and 
ALSPAC, we measured post-bronchodilator FEV1 after administration of 400 g of salbutamol (5, 11 and 
16 years in MAAS, and 15 and 24 years in ALSPAC), and assessed assessed airway hyper-reactivity (AHR) 
using methacholine challenge.22  
Details of clinical follow up, genotyping (MAAS and ALSPAC), and definitions of clinical outcomes 
(asthma,23 wheeze phenotypes,24 severe asthma exacerbations,25 airway hyper-reactivity (AHR),26 lower 
respiratory tract infections [LRTIs]27), and environmental exposures are presented in the supplementary 
appendix. 
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Statistical Analysis 
Longitudinal profile analysis to assess prototypical FEV1 trajectories: We used a latent profile model to 
assign children to their most likely group based on the profile of FEV1 over time. Latent profile modelling 
has been described extensively elsewhere.28 Briefly, we assumed that each child belonged to one of a 
set of N latent profiles, the number or size of which were unknown a priori. We used two-level random 
intercept and random coefficients regression models to examine trajectory classes with no change over 
time, and under the assumption that the profile of FEV1 changes linearly over time. The models were 
compared for goodness-of-fit using the Bayesian Information Criterion (BIC). For each child, the 
posterior probability of belonging to each of the classes was calculated, and children were assigned to 
the latent profile with the largest probability. Latent profile modelling was carried out using the gllamm 
(generalised linear latent and mixed models) package implemented in Stata (StataCorp, College Station, 
TX).  Characteristics of trajectories were investigated using multinomial regression.  
Genetic associations with FEV1 trajectories:  We constructed a weighted allele score from 77 SNPs found 
to have genome-wide evidence for association with FEV1/FVC, or FEV1 decline in adults
29 (Table S1, 
supplementary appendix). The dosage of the risk allele at each locus was multiplied by a SNP-specific 
weight (linear coefficient [beta] divided by the average of 77 linear coefficients), then averaged across 
SNPs.  SNP-specific risk alleles and weights were based on the reported meta-analysis.29 The units of the 
derived genetic score were per-beta per-SNP. Setting the ‘Normal’ trajectory as the baseline group, we 
used a multinomial logistic regression model to investigate the risk of the membership of other 
trajectories per 1-unit increase of the genetic score. The independent associations of the resulting 
genetic risk score with FEV1 trajectories in MAAS and ALSPAC were meta-analysed with fixed and 
random effect models using the method of Mantel and Haenszel (metan command in Stata). Using 
multinomial logistic regression models, we also calculated the relative risk ratios for ‘Persistently Low’ 
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(vs. ‘Normal’ trajectory) in extreme quantiles of the allelic risk score in two cohorts independently 
(deciles in ALSPAC; eight quantiles in MAAS). 
Identification of the early-life predictors of FEV1 trajectories:  We constructed a multivariable regression 
model to identify early-life predictors of subsequent latent profiles of FEV1. We carried out these 
analyses in MAAS, in which we had richer data collected in early life.  We used receiver operating 
characteristic (ROC) curves to evaluate the predictive ability of these predictors. 
Role of the funding source 
The study sponsors had no role in study design; in the collection, analysis, and interpretation of data; in 
the writing of the report; or in the decision to submit the paper for publication.  
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RESULTS 
We included 1046 participants from MAAS, 1390 from ALSPAC, and 196 from PIAF. Participant flow is 
presented in the Supplementary appendix.  
FEV1 trajectories from early school-age to young adulthood (MAAS and ALSPAC) 
We selected 4-class model in MAAS and ALSPAC (please see Supplementary appendix and Table S2).  
The posterior probability of class membership was high in both cohorts (Table S3). The proportion of 
participants and the mean FEV1 over time in each of the classes were similar across the cohorts (Table 
S4).  We labelled the classes (FEV1 trajectories) as: (1) Persistently High; (2) Normal; (3) Below Average; 
and (4) Persistently Low (Figure 1). Children within these four trajectories had stable lung function that 
tracked from age 5 to age 16 years (MAAS), and from ages 8 to 24 years (ALSPAC), with no overlap in 
FEV1 at any time. The solutions remained stable and results unchanged when we included only children 
who had spirometry on at least 3 follow-ups (Tables S5-6).   
Characteristics of children in each of the FEV1 trajectories are shown in Tables S7 and S8. Persistently 
Low trajectory was consistently associated with wheeze and asthma throughout the follow-up in both 
cohorts; in MAAS, almost half the children in this trajectory had asthma, and in ALSPAC this was 
approximately one third, significantly higher than in the rest of the population. The proportion of 
children with LRTIs in the first 3 years (data from medical records, available only in MAAS27) was 
significantly higher in the Persistently Low trajectory (32.3%) compared to the Normal trajectory 
(12.1%). Post-bronchodilator FEV1 and FEV1/FVC followed similar patterns as the baseline FEV1 in both 
cohorts. In MAAS, sRaw at age 3 years was significantly higher in Persistently Low compared to other 
trajectories, indicating diminished lung function (P=0.001). Persistently Low trajectory was significantly 
associated with AHR in both cohorts. There was no association between trajectory membership and 
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allergic sensitisation in adolescence in MAAS, or at age 7 years in ALSPAC. Sensitisation in early 
childhood in MAAS was significantly more common in Persistently Low trajectory.  
There was no difference in gender between trajectories. Birth weight was significantly higher in the 
Persistently High trajectory in ALSPAC, but not in MAAS. In MAAS, children in the Persistently High 
trajectory were less likely to be exposed to environmental tobacco smoke (ETS) compared to all others 
(Figure 2a). Children continuously exposed to ETS from birth to age 16 years were at increased risk of 
belonging to the Below Average and Persistently Low trajectories. We observed similar trends in 
ALSPAC, with Persistently High trajectory having the lowest proportion of ETS-exposed participants 
(Figure 2b). 
Genetic associations  
Genotyping data was available in 927 participants in ALSPAC, and 902 in MAAS. The weighted genetic 
score based on 77 SNPs was inversely associated with the order of FEV1 trajectories (Persistently High to 
Persistently Low) in both cohorts (Table S9). The meta-analysis is shown in Figure 3: compared with the 
Normal trajectory, the pooled relative risk ratio (95%CI) per allele was: 0.97 (0.92, 1.01), P=0.13, for 
Persistently High; 1.01 (1.00, 1.03), P=0.49 for Below Average; and 1.05 (1.00, 1.09), P=0.036 for 
Persistently Low. Results using the inverse variance method were very similar. Risk of Persistently Low 
FEV1 (vs. Normal) in 10
th decile of risk score (vs. 1st decile) was 2.03 (0.62, 6.67), p=0.24 in ALSPAC. In 
MAAS, the risk of Persistently Low FEV1 in the highest compared with the lowest of eight quantiles was 
4.19 (0.83-21.05), p=0.08. 
Do FEV1 trajectories extend back to lung function in early life (PIAF)? 
In PIAF, a 3-class model provided the optimal solution for FEV1 (Above Average, Normal and Below 
Average, Figure 4a), and a 2-class model for V′maxFRC (Above Average and Below Average, Figure 4b). 
Among children in the Below Average FEV1 trajectory, V′maxFRC was significantly lower compared to other 
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trajectories at age 1 month (P=0.05) and 6 months (P=0.018), but not at age 1 year (Table S10). Although 
children in the Below Average V′maxFRC trajectory were significantly more likely to remain in the Below 
Average FEV1 trajectory (OR=3.63, 95%CI 1.21–10.90, P=0.022), the majority of these children (~75%) 
transitioned to the Above Average (12.2%) or Normal (63.4%) FEV1 trajectories in later childhood (Figure 
4, panel c). 
Early-life predictors of FEV1 trajectories (MAAS) 
Children with recurrent severe wheeze exacerbations by age 3 years, with allergic sensitization at age 3 
years, and who have been exposed to ETS by age 3 years, were more likely to belong to the Persistently 
Low trajectory (Table S10). This set of variables provided a good predictive ability in MAAS for 
discriminating between subjects in Persistently Low from Persistently High trajectory (Figure 5, Area 
Under the ROC Curve-AUROC=90.7%, sensitivity=81.8%; specificity=80.95%), and a fair predictive ability 
for discriminating between subjects in Persistently Low from all others (Figure S1, AUROC=77.2%, 
sensitivity=81.8%; specificity=67.8%). 
We found an association between low birth weight and low childhood FEV1 trajectories. In MAAS, which 
included no preterm infants, low birth weight (LBW) at term (<2500g) was associated with Peristently 
Low FEV1 (Odds ratio 3.39 [95% CI 0.98-11.77], p=0.055). In ALSPAC, LBW adjusted for preterm (<37 
weeks) gestation at birth was associated with Persistently Low FEV1 (OR 1.98 [0.65-5.99], p=0.226, and 
Below Average FEV1 (OR 1.84 [0.91-3.73], p=0.09).   
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DISCUSSION 
In two population-based birth cohorts, using data-driven analyses we identified four distinct lung 
function trajectories extending from early school age, through mid-school age, into adolescence and 
early adulthood. Subjects assigned to the Persistently Low trajectory, representing approximately 1 in 20 
participants, had low lung function in the third decade of life, around the time of the physiological 
plateau. Individuals in this trajectory had FEV1 below 80% predicted from early childhood to the point 
beyond which lung function starts to decline with aging.3,20 In the Persistently Low trajectory, both 
baseline and post-bronchodilator FEV1 was up to 25% lower, and FEV1/FVC up to 10% lower than the 
next lowest category. This tracking of lung function from early school-age is consistent with previous 
reports from population-based studies9,10, and provides confirmatory empirical evidence of this 
phenomenon based on a hypothesis-free approach. In addition to using data-driven analyses, another 
novel feature of the present study was the extension of lung function trajectories to early childhood, 
where spirometry is not practicable, and the observation that “low” lung function recovered in the 
majority of cases. At group level, children in the Low FEV1 trajectory in PIAF had significantly diminished 
lung function in infancy (measured by V′maxFRC), which is very similar to the finding in MAAS that, as a 
group, those in Persistently Low FEV1 trajectory had significantly diminished lung function at age 3 years 
(measured by sRaw). However, comparison of lung function trajectories in infancy and in school-age in 
PIAF has shown that although infants in the Below Average V′maxFRC trajectory were significantly more 
likely than children in the higher V’maxFRC categories to be classified in the Below Average FEV1 trajectory 
in childhood, the majority of these children (~75%) transitioned to the Above Average (12.2%) or Normal 
(63.4%) FEV1 trajectories. These findings are consistent with previous results from PIAF obtained using 
standard hypothesis-testing analyses,17,30 and support the concept of postnatal “recovery” of low 
neonatal lung function. The application of the same data-driven approach to longitudinal analysis as 
used in the MAAS, ALSPAC and Tasmanian Longitudinal Health Study (TAHS),31 allows some inference to 
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the general population on the patterns of lung function from one month of age to the sixth decade. 
Disaggregation of this population into discrete trajectories suggests that the opportunity for lung 
function recovery extends beyond the neonatal period. 
Our data revealed no evidence of groups of children with declining FEV1. A report from TAHS published 
in this issue of the journal, which used a similar statistical approach to discovery of lung function 
trajectories and spanned childhood (7-18 years) and later adulthood (45-55 years), described six 
trajectories, four of which were strikingly similar to ours.31 One further trajectory with below average 
FEV1 by age 18, and accelerated decline in later adulthood after reaching the plateau, could not be 
captured within our data set. This trajectory was characterized by both childhood factors and personal 
smoking in adulthood, which were independent risk factors. Together, our studies and TAHS elucidate 
the developmental patterns of lung function through the life-course, confirm their link with COPD, and 
provide evidence that different factors affect lung function growth from those affecting lung function 
decline. We have shown that Persistently Low trajectory is determined by both genetic factors and 
early-life events. We showed relatively weak evidence that SNPs discovered through GWAS of adult lung 
function29 were associated with a low childhood trajectory of FEV1. This suggests an influence of at least 
some of the included variants on lung function in early life but, as they were derived from studies of 
adults, it is likely that they consisted of a combination of factors influencing lung function growth and 
decline. A recent study of adults with repeat lung function measures showed that genetic variants 
associated with cross-sectional lung function in adults were not associated with longitudinal decline, 
suggesting that some of the observed association may be explained by developmental influences32. We 
did not have sufficient statistical power in this sample to investigate the individual contributions of risk 
alleles, nor to construct a de novo GWAS. 
Individuals with Persistently Low FEV1 in childhood have low maximally attained lung function in early 
adulthood, and are consequently at higher risk of COPD31, with or without additional adverse exposures 
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in adulthood. Personal smoking acts as an independent risk factor which contributes to accelerated lung 
function decline in middle adulthood, predominantly among individuals with below average lung 
function.31 In this group, in addition to early-life risk factors contributing to the diminished lung function 
at physiological plateau, adverse exposures in adult life lead to COPD development. Childhood asthma 
and early-life LRTIs are associated with low lung function trajectories and higher COPD risk in both 
scenarios. We found an association between asthma reported at all available ages and persistently Low 
FEV1 trajectory. This is consistent with previously reported associations between persistent asthma in 
childhood and subsequent lung function,8, 9 but we acknowledge the potential for misclassification of 
symptoms associated with pre-existing airway obstruction and asthma diagnosis, particularly when 
relying on self-report from questionnaires for the latter. This limits interpretation of the causal pathway 
between asthma in childhood and low lung function trajectories in later life. 
Although children with severe wheeze and early sensitization had lower FEV1 throughout childhood, 
their FEV1 remained relatively stable. In contrast, a recent study of FEV1 trajectories between ages 7 and 
26 years among patients with childhood asthma described two trajectories characterized by decline 
(Normal growth and early decline, and Reduced growth with early decline).33 However, direct 
comparison with our findings is not possible, as our cohorts are population-based, and we used data-
driven approach rather than predetermined categorization to identify trajectories. In MAAS, similar 
proportions of children (approximately one third) in Persistently Low trajectory had persistent wheeze 
and transient early wheeze, whist <10% had late-onset wheezing.  This is in contrast with the Australian 
high-risk cohort, which suggested that only persistent wheeze is associated with reduced growth in FEV1 
over adolescence, but that transient wheeze is a benign condition with no sequelae.34 In MAAS, an 
important predictor of subsequent Persistently Low FEV1 trajectory was severe exacerbation of 
wheezing in early life, rather than only wheezing persistence.  Low birth weight, which is associated with 
tobacco some exposure during pregnancy and early onset wheezing in infancy was associated with low 
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childhood FEV1 trajectories in our study independently of preterm delivery. This may be explained by 
restricted intrauterine growth influencing airway development and subsequent lung function35 with an 
associated tendency to wheezing in the context of LRTIs. 
Persistently Low lung function trajectory was also identified in the Tucson cohort (comprising nearly 10% 
participants),11 and is remarkably similar to our Persistently Low trajectory, which comprised a sizeable 
proportion (3.4%-6.7%) of our study populations. Assuming that 13.3% of the population develop COPD 
(http://www.hse.gov.uk/Statistics/causdis/copd/copd.pdf), and that among these, subjects in the 
Persistently Low trajectory would likely be diagnosed with COPD,34 the calculated population 
attributable risk is 22.9%-46.7%. This also represents the estimated reduction in COPD which would 
occur if early interventions improve lung function for this group. To inform potential strategies for 
improving lung function in early adulthood, we have identified early-life risk factors associated with 
Persistently Low trajectory, which in addition to genetic factors included early-life ETS exposure, 
recurrent severe exacerbations of wheezing, and early allergic sensitisation. A recent study suggested 
that adult smoking, but not parental smoking history, can negatively influence adult lung function 
trajectory and modify the adverse impact of early-life exposures.35 Our and TAHS data demonstrate that 
both are important. We identified an association between the absence of early-life tobacco smoke 
exposure and Persistently High trajectory, which In TAHS had markedly lower risk of COPD at age 55 
years.31 Thus, while tobacco smoke exposure will not necessarily lead to a disease, the absence of this 
exposure is associated with exceptionally good lung function and subsequent health. The risk of being in 
one of the diminished lung function profiles was decreased by 76% among children who were not 
exposed to parental smoking, suggesting that ETS exposure in early childhood may be causally related to 
COPD development, and that this may be mediated via the effect of early-life exposure on subsequent 
trajectories of lung function into adulthood.  
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Strengths and limitations 
One of the limitations of our study is that it was not possible to have identical measures of lung function 
through the life-course in our cohorts. We did not measure spirometry before age five years, since 
forced expiratory manoeuvres are difficult to carry out in young children. We used different cohorts and 
age-appropriate measures of pulmonary function to make inference about the life-course (rapid 
thoraco-abdominal compression in infancy16, plethysmography in pre-school age36, spirometry from 
school age onwards), which may represent the best available approximation of what might be 
happening from birth to adulthood. Another limitation is that the questions we used contained small 
differences in wording.37 ALSPAC included pre-term babies, which may explain slightly higher proportion 
of children in the Persistently Low trajectory in ALSPAC (6.7%, compared to 3.4% in MAAS).  One of the 
strengths of this study is the ability to disambiguate the temporal structure of profiles during childhood, 
allowing us to identify patterns during the lung function growth phase. It is striking that although we 
modelled data collected at different time points, and separately for each cohort, the results indicated 
almost identical latent profiles. In PIAF, we did not observe Persistently Low FEV1 trajectory.  This is not 
surprising, given a relatively small proportion of children in this trajectory (~5%), and a considerably 
smaller size of PIAF compared to MAAS and ALSPAC. 
We wish to emphasise that our current study is exploratory in nature. Therefore, the results should 
be interpreted with caution, and need to be validated in a larger population. We are also cognizant of 
the potential effect of the withdrawal/missing data rates. We carried out our analyses under the 
assumption that data was missing at random. To test this assumption, we carried out analyses using 
both children with at least three data points available, and those with at least one time point. Both 
analyses gave consistent optimal goodness-of-fit using the BIC, and the child class assignments were 
stable across the two analyses. This suggests that the missing at random assumption was plausible, 
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given that if children with missing data points were not missing at random, there would have been a 
higher mismatch between classes. 
 
Conclusion 
Using data from population-based birth cohort studies, we demonstrated four discrete trajectories of 
FEV1 development from early childhood to young adulthood. Interventions to reduce the risk of 
Persistently Low FEV1 trajectory should start in early childhood, and should include aggressive strategies 
to reduce tobacco smoke exposure, and novel strategies to prevent early-life sensitization and 
exacerbations of early-childhood wheezing.   
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Figure 1: Mean % Predicted FEV1 over time by FEV1 trajectory:  
a) MAAS 
b) ALSPAC  
Figure 2: % Children exposed to Environmental Tobacco Smoke over time by FEV1 trajectory:  
a) MAAS  
b) ALSPAC 
Figure 3: Meta-analysis (random effects model) of weighted genetic score based on 77 SNPs with FEV1 
trajectories 
Figure 4: Lung function trajectories in PIAF: 
a) Mean % Predicted FEV1 over time by FEV1 trajectory 
b) Mean % Predicted V′maxFRC over time by V’maxFRC trajectory  
c) Membership of FEV1 trajectory in relation to the V′maxFRC trajectories 
Figure 5:   Receiver Operating Characteristic Curve showing predictive ability of a logistic regression 
analysis using the Persistently Low vs. Persistently High trajectory as the outcome (or predicted) 
measure with the following covariates: (1) recurrent wheeze with severe exacerbations by age 3 years, 
(2) at least one positive skin test by age 3 years, and (3) Environmental Tobacco Smoke exposure by age 
3 years  
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 Table R1: Summary of investigation of factors associated with probability of missing FEV1  
 
Predictor Main effect OR (SE) P value 
MAAS   
Sex (Male) 1.200 (0.098) 0.10 
BMI 0.877 (0.008) <0.001 
Asthma 1.035 (0.135) 0.80 
Use of Asthma medication 1.000 (0.132) 1.00 
Current Wheeze 0.906 (0.116) 0.44 
Sensitization (SPT) 0.930 (0.132) 0.61 
Any smoking exposure 1.305 (0.151) 0.022 
Maternal Asthma 0.966 (0.125) 0.79 
Paternal Asthma 1.094 (0.161) 0.54 
Maternal atopy (SPT) 0.960 (0.104) 0.71 
Paternal atopy (SPT) 1.048 (0.118) 0.68 
Socio-economic Status (Baseline= Managerial Group)   
Intermediate 1.101 (0.203) 0.601 
Routine 2.332 (0.519) <0.001 
Not Working 3.819 (1.491) 0.001 
ALSPAC   
Sex (Male) 1.210 (0.019) p<0.001 
BMI at 7 years 1.007 (0.005) 0.14 
Asthma (5 to 15 years) 1.116 (0.038) 0.004 
Sensitization (SPT) at 7 years 0.989 (0.025) 0.66 
Any smoking exposure (birth to 18 years) 1.947 (0.032) p<0.001 
Maternal asthma 1.004 (0.031) 0.90 
Paternal asthma 0.969 (0.032) 0.33 
Social class (ref= non-manual) 1.415 (0.020) p<0.001 
 
 
 
 
  
Necessary Additional Data
Click here to download Necessary Additional Data: Supplementary Appendix unmarked.docx
70
80
90
10
0
11
0
12
0
%
 P
re
di
ct
ed
 F
EV
1
5 8 11 16
Age(Years)
Persistently High (n=46; 4.4%) Normal (n=468; 44.7%)
Below Average (n=496; 47.4%) Persistently Low (n=36; 3.4%)
Figure
70
80
90
10
0
11
0
12
0
%
 P
re
di
ct
ed
 F
EV
1
8 15 24
Age(Years)
Persistently High (n=52; 3.7%) Normal (n=632; 45.5%)
Below Average (n=613; 44.1%) Persistently Low (n=93; 3.4%)
Figure
0
20
40
60
%
 C
hi
ld
re
n 
ex
po
se
d 
to
 E
nv
iro
nm
en
ta
l S
m
ok
in
g
0 1 3 5 8 11 16
Age(Years)
Persistently High Normal
Below Average Persistently Low
Figure
0
10
20
30
40
50
%
 C
hi
ld
re
n 
ex
po
se
d 
to
 e
nv
iro
nm
en
ta
l s
m
ok
in
g
1 2 3 4 5 6 8 10 14 16
Age (Years)
Persistently High Normal
Below Average Persistently Low
Figure
Persistent high
Below average
Persistent low
Class
ALSPAC
MAAS
ALSPAC
MAAS
ALSPAC
MAAS
Study
0.99 (0.93, 1.05)
0.94 (0.89, 1.00)
0.96 (0.92, 1.01)
1.01 (0.98, 1.03)
1.01 (0.98, 1.03)
1.01 (0.99, 1.02)
1.02 (0.97, 1.08)
1.10 (1.02, 1.18)
1.05 (0.98, 1.13)
score (95% CI)
RRR per−unit
  1.9 1.3
Figure
80
90
10
0
11
0
12
0
13
0
%
 P
re
di
ct
ed
 F
EV
1
6 11 18
Age(Years)
Persistently High (n=24; 12.2%) Normal (n=133; 67.9%)
Below Average (n=39; 19.9%)
Figure
80
10
0
12
0
14
0
16
0
%
 P
re
di
ct
ed
 V
m
ax
1 6 12
Age(Months)
Above Average (n=62; 24.5%) Below Average (n=191; 75.5%)
Figure
0
20
40
60
80
Pe
rc
en
ta
ge
 C
hi
ld
re
n 
pe
r C
la
ss
Vmax: Above Average (25%) Vmax: Below Average (75%)
FEV: Above Average FEV: Normal FEV: Below Average
Figure
0.
00
0.
25
0.
50
0.
75
1.
00
Se
ns
itiv
ity
0.00 0.25 0.50 0.75 1.00
1 − Specificity
Area under ROC curve = 0.9069
Figure
